GlycoPharma Holding ApS: Financial statements 2024
CVR: 39691558
Source: annual report 2024, Danish Business Authority
01/07/2023 – 30/06/2024
GlycoPharma Holding ApS (CVR 39691558) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK -15,530 and a net result of DKK -15,360 compared with DKK -13,637 the year before. Equity in the 2024 report amounted to DKK 696,581. The solvency ratio was 86.5%.
- Gross Profit
- DKK -15,530
- Profit/Loss
- DKK -15,360
- Equity
- DKK 696,581
- Total Assets
- DKK 805,593
- Employees
- 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | - | -16K | -15K | 697K | 0 |
| 2023 | - | -14K | -14K | 584K | - |
| 2022 | - | -8K | -7K | 407K | - |
| 2021 | - | -12K | -8K | 414K | - |
| 2020 | - | -7K | -618 | 314K | - |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningAbout GlycoPharma Holding ApS
GlycoPharma Holding ApS is a Danish company of the type Anpartsselskab based in Odense SØ, founded in 2018. The company is registered under the industry Ikke-finansielle holdingselskaber. The management consists of Anders Boysen. The company's owners include SCIENCE VENTURES DENMARK A/S, Boysen Bio ApS and Zahle Holding ApS. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK -12,525 and a net result of DKK -12,441 compared with DKK -15,360 the year before. Equity in the 2025 report amounted to DKK 684,140.